HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Reproductive Health · Adenomyosis Therapeutic Area Assessment

Intelligence report

Intelligence Report · ~15 min read

Reproductive Health · Adenomyosis Therapeutic Area Assessment

6 signals · 2 insights · 18 regulatory precedents

Type

Therapeutic Area Assessment

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 64%

Evidence

26 items

Sources

1

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Therapeutic area assessment for Reproductive Health · Adenomyosis integrates 6 signals, 2 executive insights, and 18 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. signalJul 19, 2026

    FDA Grants Approval for Clomiphene Citrate ANDA220673 by Ascent Pharms

    The FDA has granted approval for ANDA220673, a generic version of Clomiphene Citrate, submitted by Ascent Pharms.

    View detail
  2. signalJul 14, 2026

    Linzagolix Evaluated for Adenomyosis and Recurrent Implantation Failure in New Study

    A prospective case series is evaluating linzagolix for improving live birth rates in patients with adenomyosis and recurrent implantation failure.

    View detail
  3. signalJul 8, 2026

    FDA Grants Approval for Cetrorelix Acetate by Epic Pharma

    The FDA has granted approval for the ANDA218740 application for Cetrorelix Acetate submitted by Epic Pharma.

    View detail
  4. signalJul 5, 2026

    Study on Endometrial Peristalsis Impact on Pregnancy Outcomes in HRT-FET Cycles

    A prospective observational study will assess the role of endometrial peristalsis during HRT-prepared frozen embryo transfer cycles.

    View detail
  5. regulatoryJul 19, 2026

    Withdrawn | Cancer Accelerated Approvals

    This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been subsequently withdrawn, and are therefore, no longer FDA-approved.

    View detail
  6. regulatoryJul 19, 2026

    CDER proposes to withdraw approval of TAVNEOS

    Why this matters: illustrates how regulators handled a comparable approval decision relevant to Clomiphene Citrate brands; the same agency is already in play for this signal, so precedent weight is higher.

    View detail
  7. regulatoryJul 19, 2026

    Other | Cancer Accelerated Approvals

    This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been granted for supportive care products and changes to dosing or formulation.

    View detail
  8. regulatoryJul 19, 2026

    Verified Clinical Benefit | Cancer Accelerated Approvals

    This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.

    View detail
  9. insightJun 30, 2026

    Emerging Clinical Insights on Letrozole and L-Carnitine for Male Infertility Treatment

    This trial is significant as it explores potential new treatment options for male infertility, which could reshape the competitive landscape in reproductive health. The outcomes may influence product development strategies and market positioning for existing therapies. Regulatory context from FDA (Compounding Quality Center of Excellence | Recorded Webinars) supports the near-term read. Assessment grounded in 26 ranked evidence items (12 high-relevance).

    View detail
  10. insightJun 24, 2026

    Regulatory Approval of Ganirelix Acetate Enhances SUN PHARM's Market Position

    The FDA's approval of SUN PHARM's Ganirelix Acetate supplement is a significant regulatory milestone that could strengthen SUN PHARM's competitive position in the reproductive health market. This development necessitates close monitoring of its impact on market dynamics and competitor strategies in the GnRH antagonist category. Regulatory context from FDA (FDA AP — LEUPROLIDE ACETATE (SUPPL)) supports the near-term read. Assessment grounded in 26 ranked evidence items (11 high-relevance).

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Executive insights surface 2 risk-calibrated assessments for portfolio review. 18 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 1 companies with active signal exposure for competitive and portfolio shifts.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Withdrawn | Cancer Accelerated Approvals

    95%

    This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been subsequently withdrawn, and are therefore, no longer FDA-approved.

    Source: FDA

    View evidence

  • CDER proposes to withdraw approval of TAVNEOS

    95%

    Why this matters: illustrates how regulators handled a comparable approval decision relevant to Clomiphene Citrate brands; the same agency is already in play for this signal, so precedent weight is higher.

    Source: FDA

    View evidence

  • Other | Cancer Accelerated Approvals

    66%

    This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been granted for supportive care products and changes to dosing or formulation.

    Source: FDA

    View evidence

  • Verified Clinical Benefit | Cancer Accelerated Approvals

    84%

    This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.

    Source: FDA

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    84%

    Why this matters: illustrates how regulators handled a comparable approval decision relevant to Clomiphene Citrate brands; the same agency is already in play for this signal, so precedent weight is higher.

    Source: FDA

    View evidence

  • Drug Trials Snapshots: YARTEMLEA

    72%

    YARTEMLEA is a prescription drug that is MASP-2 inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

    Source: FDA

    View evidence

  • Emerging Clinical Insights on Letrozole and L-Carnitine for Male Infertility Treatment

    64%

    This trial is significant as it explores potential new treatment options for male infertility, which could reshape the competitive landscape in reproductive health. The outcomes may influence product development strategies and market positioning for existing therapies. Regulatory context from FDA (Compounding Quality Center of Excellence | Recorded Webinars) supports the near-term read. Assessment grounded in 26 ranked evidence items (12 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Regulatory Approval of Ganirelix Acetate Enhances SUN PHARM's Market Position

    65%

    The FDA's approval of SUN PHARM's Ganirelix Acetate supplement is a significant regulatory milestone that could strengthen SUN PHARM's competitive position in the reproductive health market. This development necessitates close monitoring of its impact on market dynamics and competitor strategies in the GnRH antagonist category. Regulatory context from FDA (FDA AP — LEUPROLIDE ACETATE (SUPPL)) supports the near-term read. Assessment grounded in 26 ranked evidence items (11 high-relevance).

    Source: Humanexa Insight

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Grants Approval for Clomiphene Citrate ANDA220673 by Ascent Pharms

    Regulatory Approval

  • Linzagolix Evaluated for Adenomyosis and Recurrent Implantation Failure in New Study

    Trial Update

  • FDA Grants Approval for Cetrorelix Acetate by Epic Pharma

    Regulatory Approval

  • Study on Endometrial Peristalsis Impact on Pregnancy Outcomes in HRT-FET Cycles

    Trial Update

  • Trial Evaluates Letrozole and L-Carnitine for Sperm Quality in Oligoasthenoteratozoospermia

    Trial Update

  • FDA Grants AP Status for SUN PHARM's Ganirelix Acetate Supplement

    Regulatory Approval

Insights

  • Emerging Clinical Insights on Letrozole and L-Carnitine for Male Infertility Treatment

    Reproductive Health · Male Infertility

  • Regulatory Approval of Ganirelix Acetate Enhances SUN PHARM's Market Position

    Reproductive Health · GnRH Antagonist

Companies

  • Epic Pharma

    6 signals

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.